Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Immuneering Corp Director's Dealing 2022

May 27, 2022

32973_dirs_2022-05-27_a49bec25-f4c7-49e2-986a-0434df1a5e4e.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Immuneering Corp (IMRX)
CIK: 0001790340
Period of Report: 2022-05-25

Reporting Person: Hall Brett Matthew (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2022-05-25 Class A Common Stock P 2551 $3.92 Acquired 332685 Direct